All News

lung%2Cbright.jpg

Pulmonary Manifestations of Rheumatic Disease in Asymptomatic Patients

Meral K. El Ramahi, MD, FACP, FACR

In clinical practice, pulmonary manifestations of rheumatic medical diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and peripheral spondyloarthritis (pSpA) are typically not screened for upon diagnosis of a rheumatic disease in patients without any signs or symptoms suggest

Read Article
RheumNow Podcast square

Late Should Not Be Less (11.3.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports and regulatory approvals from the past week on RheumNow.com.

Read Article
vaccination.jpg

H. Zoster Subunit Vaccine Efficacy with JAK Inhibitor Therapy

Jack Cush, MD

JAK inhibitors are known to increase the risk of herpes zoster infections between between 3-5 fold.  Two recent reports suggest variable efficacy when JAK inhibitor (JAKi) treated patients are vaccinated with the recombinant herpes zoster subunit vaccine (RZV). 

Read Article
RheumNow Podcast square

Methotrexate in OA (10.20.2023)

Jack Cush, MD

Dr. Jack Cush discusses the news, journal articles and regulatory actions. This week we discuss JAKne, DLE and SLE and more.

Read Article
FDA%20approved.jpg (keep)

FDA Approves IV Secukinumab

Jack Cush, MD

On Oct. 6, 2023, Novartis announced the US Food and Drug Administration (FDA) approved an intravenous (IV) formulation of secukinumab (Cosentyx) for use in treating adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA).

Read Article
DESIR cohort update in Abs #0513 shows axSpA pt imaging doesn't "worsen" after pregnancy. However, following 1st pregnancy, can see slight increase in L SIJ score, but typically not enough to define "worsening." #ACR23 https://t.co/HaYj3RQGFb @rheumnow https://t.co/5MQCXS1Kat
Dr. Rachel Tate  ( View Tweet)
Dr. Seo shares an interesting case report on the use of anti-TRBV9 Ab in a patient with AS. Another potential treatment option for AS?šŸ§ Something to watch out for in the future. #ACR23 @RheumNow @rheumarhyme https://t.co/y6mQ756TKK
sheila  ( View Tweet)
In bDMARD-IR AS patients, UPA led to numerically greater improvements vs PBO in physical activity as measured by a wearable device over 14 wks, especially in sedentary patients. #ACR23 Abs #0530 https://t.co/6Me2XctK6D @rheumnow https://t.co/c6E2GfAGt4
Dr. Rachel Tate  ( View Tweet)
Large Chicago study Abs #0535 at #ACR23 biologic tx prescribed more often for males, Non-Hispanic Blacks and Latinx in AS. Low SES, measured by SDI, and insurance status did not affect if pt received bDMARD. https://t.co/MdDuNPMCC9 @rheumnow https://t.co/Oa9aC3rbb0
Dr. Rachel Tate  ( View Tweet)
Join us tonight at 6pm PT/ 9pm ET for our daily #ACR23 recap. https://t.co/0RDwTdzhwS
Dr. John Cush RheumNow ( View Tweet)
Do you check fecal calprotectin levels in your SpA pts? Maybe you should. #ACR23 Abs #0495 EISER study shows increased prevalence of undiagnosed IBD in SpA that may be detected in our clinics with fecal calprotectin levels prior to GI evaluation. https://t.co/d7BbrUd570 @rheumnow https://t.co/COcKdvjWnr
Dr. Rachel Tate  ( View Tweet)
Some key facts on Axial Spondyloarthritis, the overall ratio of M:F is 1:1, so not a male predominant condition #AxSpa Ogdie A #ACR23 @RheumNow https://t.co/mfp9YIIdue
Dr. Antoni Chan  ( View Tweet)
This is the real challenge of nr-axSpA: knowing where people land, and who will radiographically progress. Alexis Ogdie #ACR23 Review Course @RheumNow https://t.co/r4y6nwfvhG
David Liew drdavidliew ( View Tweet)
RHEUM SURVEY: Your choice of a biologic in SpA patients is mostly influenced by? Respond here>> https://t.co/AtX4vZBvIT https://t.co/CgzROe8irB

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of TNFi tapering in 108 axSpA patients in remission. Gradual tapering over 2 yrs resulted in flares in 99% (108). - 27% flared at 2/3 dose - 20% at 1/2 dose - 27% at 1/3 dose - 25% w/ discontinuation WHY WOULD YOU DO THIS? I DONT! https://t.co/g8L7E4lcqG https://t.co/oaBILUrlmd

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Live registration is NOW OPEN! Early bird pricing through 11/30/2023. Register today! https://t.co/1SjBiM7Daj https://t.co/w2cFcj85r5

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Live registration is NOW OPEN! Early bird pricing through 11/30/2023. Register today! https://t.co/7OsdPYWukv https://t.co/QoCxR04bJD

Links:

Dr. John Cush RheumNow ( View Tweet)
Sleep problems in SpA & PsA? Study of 201 pts shows 43% of axSpA and 47% of PsA pts reported sleep problems. In both poor sleep assoc w/ dz activity. In axSpa it signif assoc w/ Dz activity (OR 8.45),biologic use (OR .24), & CRP levels (OR .16) https://t.co/7juI2Dghjh https://t.co/SxCaJgTmeQ

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA Approves IV Secukinumab On 10/6/23, Novartis announced the FDA approved an IV formulation of secukinumab (Cosentyx) for use in treating adults with PsA, ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) https://t.co/zv7b98ZUjS https://t.co/1rXjYIbLpw

Links:

Dr. John Cush RheumNow ( View Tweet)
Registration is now open! Early bird pricing is available until 11/30/23. See you there! https://t.co/zjXyldwlyl https://t.co/CpQ00745c1

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×